Kate Cwynarski

Going to ASCO this weekend? Come say hi to our team Ann LaCasce, Nina Shah , David Wright & see our global Gender Equity Survey results.
Poster board 396, June 1st, 9-12pm

More details about the survey to come at our EHA presentation June 14th, 5:15pm in Amber Hall 3+4

T cell malignancies after CAR T cell therapy in the DESCAR-T registry - PubMed The risk of T cell malignancies after chimeric antigen receptor (CAR) T cell therapy is a concern, although the true incidence remains unclear. Here we analyzed the DESCAR-T registry database, encompa...

T cell malignancies after CAR T cell therapy in the DESCAR-T registry

Of 3,066 patients:
(2,536 B cell lymphoma, 162 ALL, 368 MM)
ONLY 1 (0.03%) pt dev a T cell malignancy after CAR T infusion

@RemyDulery
Roch Houot

@NatureMedicine

pubmed.ncbi.nlm.nih.gov/39779930/

Patient-entered data in Waldenstrom’s: WhiMSICAL delivers real world outcomes and empowers patients to be partners in research. Congrats Ryan Low, @judithtrotman.bsky.social IMWF, WMozzies #ASH24 #ASHKudos

Such a beautiful energy @womeninlymphoma.bsky.social @judithtrotman.bsky.social and plans for the next WiL projects #lymsm #ASH24

It’s the end of #ASH24. Enjoying some time in La Jolla with wonderful friends before heading back on the Heathrow red eye!

PET/CT-derived coronary calcium score may predict cardiac complications in anthracycline-treated lymphoma patients Key Points. Coronary calcium score calculated on pre-treatment PET/CT identifies lymphoma patients at risk of cardiac events after anthracycline therapyCor

Our multidisciplinary team identified that in #lymsm patients having anthracycline, coronary artery calcium measured on baseline PET/CT predicts cardiac events

ashpublications.org/bloodadvance... #hemesky @onjcri.bsky.social

Just out at JAMA Oncology, led by Parsa Erfani

We review why many efforts to improve access to oncology medicines around the world have failed so far, especially compared to infectious diseases, & offer potential strategies to improve global pharmacoequity

jamanetwork.com/journals/jam...

🌏 Please join our free educational #CareerDevelopment webinar next Wed Nov 20 with Laurence Hollobon + panel of emerging global women in lymphoma⚕️

👉Please register us06web.zoom.us/webinar/regi...

With thanks to Gilead Sciences, IFLI, Eli Lilly & Co, Lymphoma Australia